{"document_type": "article", "byline": {"person": [{"role": "reported", "firstname": "Andrew", "organization": "", "rank": 1, "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "news_desk": "Business", "slideshow_credits": null, "abstract": "Food and Drug Administration approves Roche's new immunotherapy drug, Tecentriq, to treat bladder cancer; drug belongs to class of medicines called checkpoint inhibitors.", "multimedia": [{"type": "image", "url": "images/2016/05/19/business/19IMMUNE/19IMMUNE-thumbWide.jpg", "legacy": {"wide": "images/2016/05/19/business/19IMMUNE/19IMMUNE-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "width": 190, "subtype": "wide", "height": 126}, {"type": "image", "url": "images/2016/05/19/business/19IMMUNE/19IMMUNE-articleLarge.jpg", "legacy": {"xlarge": "images/2016/05/19/business/19IMMUNE/19IMMUNE-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "961"}, "width": 600, "subtype": "xlarge", "height": 961}, {"type": "image", "url": "images/2016/05/19/business/19IMMUNE/19IMMUNE-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/05/19/business/19IMMUNE/19IMMUNE-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "width": 75, "subtype": "thumbnail", "height": 75}], "headline": {"print_headline": "F.D.A. Approves Immunotherapy Drug for Treatment of Bladder Cancer", "main": "F.D.A. Approves an Immunotherapy Drug for Bladder Cancer"}, "print_page": "3", "keywords": [{"value": "Roche Holding AG", "is_major": "Y", "rank": "1", "name": "organizations"}, {"value": "Bladder Cancer", "is_major": "Y", "rank": "2", "name": "subject"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "3", "name": "subject"}, {"value": "Food and Drug Administration", "is_major": "Y", "rank": "4", "name": "organizations"}, {"value": "Immune System", "is_major": "N", "rank": "5", "name": "subject"}], "snippet": "The drug, Tecentriq from Roche, works by using the body\u2019s immune system against tumors, and is the first drug of its type approved for bladder cancer.", "source": "The New York Times", "lead_paragraph": "The drug, Tecentriq from Roche, works by using the body\u2019s immune system against tumors, and is the first drug of its type approved for bladder cancer.", "word_count": "1008", "pub_date": "2016-05-19T00:00:00Z", "subsection_name": null, "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/05/19/business/food-and-drug-administration-immunotherapy-bladder-cancer.html", "_id": "573ccd9338f0d81236fa7ee1"}